You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,213,425

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,213,425

Title:	Role of N-2-hydroxy-ethyl-piperazine-N\'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury
Abstract:	Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.
Inventor(s):	Danhof; Ivan E. (Grand Prairie, TX)
Assignee:	BESPOKE BIOSCIENCE, LLC (Dallas, TX)
Application Number:	15/725,007
Patent Claims:	1. A method of treating pain and post-chemotherapy cognitive impairment caused by demyelination in a human subject following a treatment for a cancer comprising the steps of: identifying a human subject in need for treatment against the pain post-chemotherapy cognitive impairment caused by demyelination following a treatment for the cancer; and administering a pharmaceutical composition comprising N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) and derivatives thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers once daily at a dosage of 10-100 mg/kg of body weight, wherein the pharmaceutical composition is administered orally, subcutaneously, parenterally, intravenously, peritoneally, or intramuscularly that is sufficient to treat the pain and post-chemotherapy cognitive impairment caused by demyelination. 2. The method of claim 1, wherein the cancer is a pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, lung cancer, cervical cancer, gastric cancer, liver cancer, melanomas, brain tumors, multiple myeloma, prostate cancer, or bladder cancer. 3. The method of claim 1, wherein the composition is used to treat post-chemotherapy cognitive impairment following a breast cancer treatment. 4. The method of claim 1, wherein the HEPES is dissolved in sterile water for injection.

Details for Patent 10,213,425

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2029-09-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.